ArticleArthritis and rheumatism2011
Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.
Article in Arthritis and rheumatism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 77 citations in OpenAlex.
- An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women.Journal of clinical psychopharmacology · 2017Trial
- Eosinophilic fasciitis.Medicina clinica · 2025Review
- A Scoping Review of Eosinophilic Pneumonia and Antidepressants: An Association Not to Be Overlooked.Diseases (Basel, Switzerland) · 2025Review
- Postnatal Development of the Circadian Rhythmicity of Human Pineal Melatonin Synthesis and Secretion (Systematic Review).Children (Basel, Switzerland) · 2024Review
- Clinical, mechanistic, and therapeutic landscape of cutaneous fibrosis.Science translational medicine · 2024Review
- The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review.Central-European journal of immunology · 2024Review
- Is Melatonin the "Next Vitamin D"?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements.Nutrients · 2022Review
- Analytical Chemistry of Impurities in Amino Acids Used as Nutrients: Recommendations for Regulatory Risk Management.Nutrients · 2022Review
- Detection of impurities in dietary supplements containing L-tryptophan.Amino acids · 2022Article
- Safety evaluation of dried L-tryptophan fermentation product in Sprague-Dawley rats.Toxicology reports · 2022Article
- Impact of Pharmacotherapy on Insomnia in Patients with Alzheimer's Disease.Drugs & aging · 2021Review
- The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis.Orphanet journal of rare diseases · 2021Article
- Epidemics and outbreaks of peripheral nervous system disorders: II. Toxic and nutritional causes.Journal of neurology · 2021Article
- Melatonin Use in Pediatrics: Evaluating the Discrepancy in Evidence Based on Country and Regulations Regarding Production.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Review
- [Hypereosinophilic syndrome and other rheumatic diseases with hypereosinophilia].Zeitschrift fur Rheumatologie · 2019Review
- Insomnia in Elderly Patients: Recommendations for Pharmacological Management.Drugs & aging · 2018Review
- Risk factors and disease mechanisms in myositis.Nature reviews. Rheumatology · 2018Review
- Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.Clinical reviews in allergy & immunology · 2017Review
- Morphea and Eosinophilic Fasciitis: An Update.American journal of clinical dermatology · 2017Review
- Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.Drug safety · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Eosinophilia-myalgia syndrome (EMS) is characterized by subacute onset of myalgias and peripheral eosinophilia, followed by chronic neuropathy and skin induration. An epidemic of EMS in 1989 was linked to consumption of L-tryptophan that had originated from a single source. Following the ban by the Food and Drug Administration (FDA) on the sale of L-tryptophan, the incidence of EMS declined rapidly. Moreover, no new cases have been described since the FDA ban was lifted in 2005. We report the clinical, histopathologic, and immunogenetic features of a new case of L-tryptophan-associated EMS, along with evidence of activated transforming growth factor β and interleukin-4 signaling in the lesional skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.